Published data regarding the overall risks and incidence of hypertension and proteinuria associated with lenvatinib remain unclear.

Background: Chemotherapy-induced nausea and vomiting (CINV) represent prevalent and distressing adverse effects among cancer patients, substantially compromising treatment compliance and quality of life. This systematic review and meta-analysis evaluate the therapeutic efficacy of aromatherapy in managing CINV, with the objective of informing evidence-based clinical decision-making in supportive cancer care. Methods: We systematically searched PubMed, Embase, and Cochrane Library for randomized controlled trials (RCTs) assessing aromatherapy's effects on CINV. Two reviewers independently screened studies, extracted data, and evaluated bias risk. Meta-analysis was performed using RevMan 5.4, with outcomes expressed as odds ratios (ORs) or mean differences (MDs) with 95% confidence intervals (CIs). Results: Twelve RCTs (n = 1,572) were included. Aromatherapy significantly reduced acute nausea (OR = 0.46, 95% CI 0.29-0.73), acute vomiting (OR = 0.56, 95% CI 0.40-0.79), and delayed nausea (OR = 0.64, 95% CI 0.47-0.88). However, no significant effects were observed for delayed vomiting (OR = 0.72, 95% CI 0.39-1.34), VAS scores (MD = -1.30, 95% CI -2.76-0.16), or INVR scores (MD = -1.67, 95% CI -3.67-0.32). No publication bias was detected (p > 0.05). Conclusion: The existing body of evidence suggests that aromatherapy may function as a valuable adjunctive therapy in mitigating chemotherapy-induced nausea, especially during the acute phase. Nevertheless, its efficacy in managing vomiting and symptoms in the delayed phase remains uncertain. Future research efforts should focus on conducting large-scale, methodologically robust RCTs that employ standardized aromatherapy protocols and incorporate longitudinal assessments of outcomes and understanding the biological mechanisms associated with aromatherapy therapeutic effects.

Chemotherapy, as one of the main treatments for patients with colorectal cancer (CRC), brings clinical benefits with varying degrees of gastrointestinal reactions. Post-chemotherapy diarrhea is one of the factors affecting the quality of life of cancer patients. In severe cases, it can cause interruption of the chemotherapy process and even be life-threatening. Probiotics' role in preventing post chemotherapy diarrhea in CRC patients has not been proven.

Cardiotoxicity is a recognized adverse effect associated with anti-HER2 therapies. The Trastuzumab-mediated cardiac dysfunction is not dose-dependent and lacks ultrastructural changes, allowing potential recovery after a few months. There is no consensus on the management of patients who develop cardiotoxicity. This meta-analysis aims to assess the safety of the permissive cardiotoxicity of Trastuzumab in patients with breast cancer. We searched PubMed, Cochrane Library, and Embase up to October 2023 for retrospective or prospective studies that investigated the safety of Trastuzumab in patients with breast cancer who continued Trastuzumab therapy after asymptomatic ejection fraction (EF) decline. We conducted a pooled meta-analysis for the subsequent cardiac events, cardiac mortality, and all-cause mortality. We assessed the quality of included studies using the Newcastle-Ottawa Scale and ROBIN-1 tool. A total of eight cohort studies (six retrospective and two prospective), comprising 222 patients, were found eligible and were included in our analysis. The pooled incidence of cardiac events, cardiac-related mortality, and all-cause mortality was 18% (95% CI 13% to 24%), 5% (95% CI 2% to 10%), and 8% (95% CI 2% to 28%), respectively. The incidence of symptomatic or severe cardiac events was lower in those who received cardioprotective medications concomitant with Trastuzumab. Most patients received either angiotensin-converting-enzyme inhibitors, beta-blockers, or a combination of both. Continuation of planned Trastuzumab therapy with concomitant use of cardioprotective medications can be a safe and effective approach for breast cancer control in patients with asymptomatic EF decline.

To assess the effectiveness and safety of sacituzumab govitecan in metastatic breast cancer (MBC), we performed a meta-analysis of randomized controlled trials comparing sacituzumab govitecan with chemotherapy.

Hypersensitivity reactions (HSRs) to essential chemotherapy create treatment barriers in cancer care globally. Conventional 3-bag protocols (3BPs) for rapid drug desensitization (RDD) present operational challenges that may inadvertently exacerbate health care disparities.

Oral mucositis (OM), as a common adverse effect in patients with chemotherapies, affects the convalescent quality of life. Currently, an increasing number of mouthwashes have been used to improve the incidence of OM in patients undergoing with radiotherapy and chemotherapy. Most studies are comparisons of two arms or three groups, resulting in the lack of direct comparative trial evidence for all care fluids.Therefore, it is not clear which mouthwash is better for preventing the occurrence of OM in patients. This study compares the preventive effects of13 mouthwashes currently used to treat OM in different countries.

Non-clear cell renal cell carcinomas (nccRCCs) present considerable challenges owing to their heterogeneity and limited clinical trial representation. Understanding the benefits of combining immunotherapy and targeted therapy for these subtypes is crucial for improving patient outcomes.

Cancer immunotherapy enhances the prognosis of cancer patients; however, it has been shown to be associated with potentially fatal cardiac risks, which requires further confirmation. This study aimed to explore the cardiotoxicity of immune checkpoint inhibitors (ICIs) in solid tumors.

To evaluate the evidence for tamoxifen induced alterations of retina blood flow in macula region, using Optical Coherence Tomography Angiography (OCTA).

Some studies have developed machine learning (ML) models for the prediction of pneumonitis following immunotherapy and radiotherapy for patients with lung cancer (LC). However, the prediction accuracy of these models remains a topic of debate. Thus, this study aims to summarize the advantages of ML methods in the early prediction of radiation pneumonitis (RP) and checkpoint inhibitor pneumonitis (CIP) in LC patients. PubMed, Cochrane, Embase, and Web of Science were searched up to March 23, 2025. The Prediction Model Risk of Bias Assessment Tool (PROBAST) was utilized to explore the risk of bias (RoB) in the included studies. A subgroup analysis was conducted based on variables including radiomics, dosiomics, and clinical characteristics. Fifty-six studies comprising 12,803 LC patients were included. Of these, 43 studies focused on the early prediction of RP, 11 studies on CIP, and 2 studies on differentiating RP and CIP. The meta-analysis revealed that the c-index of dosiomics-based models, radiomics-based models, and models based on radiomics and clinical characteristics for predicting RP was 0.82 (95% CI: 0.76-0.87), 0.80 (95% CI: 0.71-0.89), and 0.90 (95% CI: 0.86-0.94), respectively. In the prediction of CIP, the c-index for the clinical characteristics model was 0.83 (95% CI: 0.81-0.85), while the integrated radiomics and clinical characteristics model achieved a c-index of 0.86 (95% CI: 0.80-0.92). The ML-based models exhibit strong performance for predicting RP and CIP. Models that integrate dosiomics and radiomics demonstrate superior predictive performance for RP. In addition, hybrid models combining radiomics with clinical features provide excellent predictive value for CIP.

Ovarian cancer (OV) is the most prevalent and lethal gynecologic malignancy globally. Cisplatin remains the first-line chemotherapeutic regimen for OV; however, chemotherapy resistance poses a persistent clinical challenge in gynecologic oncology. Parthenolide, a naturally derived phytochemical, exhibits broad-spectrum antitumor activity. Recent studies suggest that parthenolide may reverse cisplatin-resistance in OV when used in combination therapy. This study aims to elucidate the molecular targets and mechanisms underlying parthenolide-mediated reversal of cisplatin-resistance by integrating network pharmacology and molecular docking approaches.

The aim of this systematic review and meta-analysis is to determine the efficacy and safety of selective internal radiation therapy (SIRT) using yttrium-90 (Y-90) combined with immune checkpoint inhibitors (ICIs) in the treatment of hepatocellular carcinoma (HCC).

Breast cancer (BC) is the most common cancer in women. Taxanes are widely used, but their neurotoxicity affects patients' quality of life. Genetic polymorphisms in CYP450 enzymes influence taxane metabolism, leading to variability in toxicity risk.

Recent research suggests a link between KRAS mutations and the effectiveness of ICIs, as KRAS-driven tumors may possess unique immunogenic features that influence the tumor microenvironment. These mutations can increase tumor mutation burden (TMB) and neoantigen load, potentially leading to improved responses to ICIs. This meta-analysis aims to consolidate existing evidence on the impact of KRAS mutations as a predictive factor for survival and treatment outcomes in patients with advanced NSCLC treated with ICIs. A comprehensive search strategy was designed by a biostatistician and pulmonologist, targeting PubMed, Web of Science, and Scopus databases up to May 2022. The outcomes assessed included overall survival (OS) and progression-free survival (PFS), reported as log hazard ratios (HRs) with corresponding standard errors (SEs). A pooled estimate of the HR effect size was calculated using Review Manager (RevMan, Cochrane Collaboration, London, UK). Heterogeneity among studies was evaluated using the Cochran Q test and the I2 statistic. Ultimately, 10 articles were deemed suitable for inclusion in the systematic review from a total of 8722 screened titles and abstracts. The presence of KRAS+ mutations had a significant prognostic factor for better OS in NSCLC patients treated with checkpoint inhibitors (HR = 0.89, 95% CI: 0.79-0.99) and for better PFS in NSCLC patients treated with checkpoint inhibitors (HR = 0.72, 95% CI: 0.59-0.87). In conclusion, our study indicates that KRAS mutations may serve as a potential positive predictive biomarker in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitor monotherapy.

Platinum-based chemotherapy significantly increases the risk of nausea and vomiting, which can impair the treatment's efficacy and the patient's quality of life. This meta-analysis examines the incidence and risk factors of platinum-based chemotherapy-induced nausea and vomiting (PINV) in patients treated with this chemotherapy.

Uterine damage after pelvic radiotherapy or total-body irradiation is well described, with decreased uterine volume and high obstetrical morbidity. Some recent studies have reported a smaller uterus in child, adolescent, and young adult cancer survivors treated with chemotherapy only. This systematic review investigated the long-term effects of gonadotoxic therapy on uterine volume during childhood, adolescence, and young adulthood.

Osimertinib, a third-generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI), is the standard of care for patients with EGFR-mutated Non-Small Cell Lung Cancer (NSCLC). While clinically effective, concerns have emerged regarding its potential cardiotoxicity. This study aims to systematically evaluate the prevalence and types of cardiotoxicity associated with Osimertinib.

To compare the efficacy and safety of first-line treatments for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC).

To evaluate the adverse events associated with tunneled central venous catheters (CVCs) and totally implantable venous access device (TIVAD) in patients of pediatric oncology undergoing chemotherapy.